Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2001

View Archived Issues

CS-023 may have advantages over imipenem and meropenem according to preclinical data

Inhibition of PI3K enhances human sperm motility

AGI-1067 advances to phase IIb for treatment of restenosis and atherosclerosis

Targeted anti-Gram-positive oxazolidinone shows promise for resistant infections

Oritavancin phase III data, potential in anthrax infections discussed at ICAAC meeting

Adjunctive therapy with Actimmune in a serious invasive fungal infection

Vasomax amendment submitted in the U.K.

Pharmacia returns U.S. rights to Ambien to Sanofi-Synthelabo

Schering-Plough highlights promising therapeutics in development pipeline

Amylin anticipates filing NDA amendment for Symlin within the next six months

Salix seeks approval for rifaximin in travelers' diarrhea

Tularik presents SAR in a novel class of non-nucleoside anti-HCMV agents at ICAAC meeting

AstraZeneca and Lilly to collaborate on clinical trials with ZD-1839 and gemcitabine combination

Allopurinol reverses mechanoenergetic uncoupling in cardiomyopathy

Muscarinic agonist identified at Acadia reduces intraocular pressure in monkeys

New antiinflammatory steroids useful for asthma and various other conditions

N/OFQ receptor ligands useful as analgesics discovered by GSK

Boehringer Ingelheim patents compounds for asthma and other inflammatory disorders

Glycopeptide antibacterial agents designed by Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.